BioNTech SE Sponsored ADR (NASDAQ:BNTX) Holdings Cut by CenterBook Partners LP

CenterBook Partners LP lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 43.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,417 shares of the company's stock after selling 84,701 shares during the quarter. BioNTech makes up 0.6% of CenterBook Partners LP's portfolio, making the stock its 29th largest holding. CenterBook Partners LP's holdings in BioNTech were worth $9,964,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BNTX. Banque Cantonale Vaudoise bought a new stake in BioNTech in the 1st quarter valued at $36,000. Jones Financial Companies Lllp increased its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares during the last quarter. Allianz SE bought a new stake in BioNTech in the 4th quarter valued at $90,000. Costello Asset Management INC bought a new stake in BioNTech in the 1st quarter valued at $91,000. Finally, Goodman Advisory Group LLC bought a new stake in BioNTech in the 1st quarter valued at $105,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded up $1.84 on Wednesday, reaching $112.49. The company's stock had a trading volume of 786,503 shares, compared to its average volume of 941,517. The stock's 50-day moving average is $104.07 and its two-hundred day moving average is $106.76. BioNTech SE Sponsored ADR has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The stock has a market capitalization of $27.04 billion, a P/E ratio of -33.09 and a beta of 1.29.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BNTX. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Bank of America decreased their price target on shares of BioNTech from $127.00 to $126.00 and set a "buy" rating for the company in a research note on Wednesday. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective on the stock. Morgan Stanley set a $133.00 target price on BioNTech and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, JPMorgan Chase & Co. lowered their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $136.58.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.